Legend BiotechLEGN
Recorded

Legend Biotech 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration49 minParticipants18

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome to Legend Biotech third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. I would now like to turn the call over to Caroline Paul, Senior Director of Investor Relations. You may begin. Good morning.

Caroline PaulSenior Director of Investor Relations

This is Caroline Paul, Senior Director of Investor Relations at Legend Biotech. Thank you for joining us today to review our third quarter 2026 performance. Prior to this call, we issued a press release announcing our financial results, which can be found on the Legend Biotech Investor Relations website. Joining me on today's call are Ingrid Zhang, our Chief Executive Officer, Alan Bash, President of CARVYKTI, and Carlos Santos, Chief Financial Officer. Following the prepared remarks, we will open the call for Q&A. Yuhong Qiu, our Interim Head of R&D, will also join us for the Q&A session. During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied herein.

Caroline PaulSenior Director of Investor Relations

These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be found under the Investors section of our company website. In addition, adjusted net income or loss is a non-IFRS metric. This non-IFRS financial measure is in addition to and not a substitute for or superior to measures of financial performance prepared in accordance with IFRS. There are a number of limitations related to the use of these non-IFRS financial measures versus their closest IFRS equivalents. However, we believe that providing information concerning adjusted net income or loss and adjusted net income or loss per share enhances an investor's understanding of our financial performance. Our press release includes IFRS to non-IFRS reconciliations for these measures. With that, I will now turn the call over to Ingrid.

Ingrid ZhangCEO

Thank you, Caroline, and good morning, everyone. Before reviewing our third quarter results, I would like to share a few thoughts, as this is my first earnings call as Legend's CEO. Over the past several weeks, I have spent time with colleagues across the entire organization and engaged with physicians and other stakeholders working to bring CARVYKTI to patients around the world. What has become clear to me is the strength of what Legend has built. Legend has demonstrated its ability to bring innovative cell therapy to market at meaningful scale through strong science, manufacturing excellence, and a deep focus on patients. This is incredibly difficult to accomplish and speaks to the foundation that exists that we can leverage for the rest of the pipeline. I have also been impressed by the quality of our people and the collaborative culture across the organization. Together, these strengths reinforce my confidence in Legend's future.

Ingrid ZhangCEO

I joined Legend because I believe the opportunity ahead is significant. CARVYKTI continues to expand its impact for patients with multiple myeloma, while our pipeline provides an opportunity to extend our leadership in cell therapy for years to come. My priorities as CEO are clear. Number one, maximize CARVYKTI. Number two, advance our next-generation pipeline. And number three, strengthen execution on all fronts to deliver sustained profitability. We enter this next chapter from a position of financial and commercial strength, with a differentiated asset that has extensive real-world results, an innovative platform, and a team focused on delivering for patients and external stakeholders. With that, let me turn to our third quarter highlights. Slide seven, please. In the third quarter, CARVYKTI net trade sales increased approximately 36% year-over-year to $710 million.

Ingrid ZhangCEO

Growth was driven by continued adoption in the early line settings in the U.S. and new country launches, with net trade sales increasing 19% in the U.S. and 86% outside the U.S. on a year-over-year basis. We also continue to expand global patient access, reaching 373 active treatment sites globally. During the quarter, we presented important long-term follow-up data from the CARTITUDE-2 cohort A study at the 2026 International Myeloma Society Annual Meeting, or IMS. These results further strengthen the growing body of evidence supporting the potential impact of CARVYKTI in earlier line multiple myeloma. We also received FDA clearance of our IND application for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR T therapy in relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma. This represents an important achievement step as we advance our next generation of cell therapy programs. Slide eight, please. Turning to our IMS results, one of the most important data updates during the quarter came from a five-year follow-up analysis of CARTITUDE-2 cohort A in patients with relapsed or refractory multiple myeloma after one to three prior lines of therapy.

Ingrid ZhangCEO

The data demonstrated strong durability responses. Five years after single CARVYKTI infusion, half of the 20 patients from CARTITUDE-2 cohort A remained alive and progression-free without further anti-myeloma treatment, compared with 33% in CARTITUDE-1. Five-year overall survival was 69%, compared with 51%, respectively. Importantly, the safety profile remained consistent with the known profile of CARVYKTI, with no new CAR T-cell-related neurotoxicity reported during the extended follow-up period. Taken together, we believe these findings support the use of CARVYKTI in earlier line settings, which may increase the likelihood of achieving durable treatment-free remission for patients living with multiple myeloma.

Ingrid ZhangCEO

Earlier use of CARVYKTI was also reinforced by recent updates to NCCN guidelines, which Alan Bash will explain in detail. As shown on the next slide, we continue to evaluate CARVYKTI through the CARTITUDE-5, CARTITUDE-6, and CARTITUDE-10 studies. These programs represent an important opportunity to evaluate CARVYKTI in frontline settings, including transplant-ineligible and transplant-eligible patients, and essential to our long-term strategy for that asset. Slide nine, please. Beyond CARVYKTI, we are advancing our in vivo CAR T programs, along with additional programs across hematological malignancies and solid tumors. Slide 10, please. During the quarter, we achieved FDA clearance of IND for LB2501, representing an important step forward for our in vivo CAR T platform.

Ingrid ZhangCEO

As you might recall from our EHA presentation over the summer, our NHL program, designed as a CD19/CD20 dual-targeting therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, demonstrated compelling early data with a 100% ORR and 83% CR rate for six patients at dose level 2. As you may have seen in the abstract for the upcoming American Society of Hematology annual meeting, we recently provided an update with 19 patients across three dose levels, compared to the 12 patients across two dose levels at EHA. We are very pleased that LB2501 continues to demonstrate a favorable safety profile and encouraging efficacy, with remarkable 100% ORR and 100% CR rates at dose level 2, with a median follow-up of nearly five months. We intend to share additional updates across the dose levels at ASH.

Ingrid ZhangCEO

In terms of clinical development plans, the phase I-A study for LB2501 is intended to confirm and further characterize dose selection in the U.S. clinical setting, based in part on insights from the ongoing IIT study in China, enabling the program to potentially transition quickly into phase I-B. Phase I-B is planned to broaden the evaluation of LB2501 across multiple B-cell malignancies, including DLBCL, MCL, and CLL, as well as further inform patient selection. Following this, we intend to advance LB2501 into phase II in appropriately selected patient populations to further characterize and confirm efficacy and safety. Regarding LB2505, our BCMA-directed therapy for multiple myeloma, we do not have further updates to share at this time, but we remain focused on dosing patients as soon as possible.

Ingrid ZhangCEO

As a reminder, this program falls under the terms of our agreement with Janssen and Johnson pertaining to BCMA-directed CAR T programs in multiple myeloma. Overall, we are encouraged by the breadth of opportunities represented across our pipeline and remain focused on disciplined execution. Slide 11. Legend remains well-positioned for long-term growth. Commercially, CARVYKTI remains the leading CAR T therapy in multiple myeloma, supported by expanding global demand, earlier line adoption, and a growing body of long-term clinical evidence. Operationally, we ended the quarter with approximately $853 million in cash equivalents, and time deposits, and remain focused on achieving company-wide profitability for full-year 2026 on an adjusted net income basis. Across our pipeline, we continue to advance our differentiated cell therapy programs, including our next-generation in vivo platform. Taken together, these strengths provide a solid foundation for sustainable long-term growth and value creation.

Ingrid ZhangCEO

With that, I will turn the call over to Alan Bash for a commercial update.

Alan BashPresident of CARVYKTI

Thank you, Ingrid. CARVYKTI continues to deliver solid global growth during the quarter. Net trade sales increased approximately 36% year-over-year to approximately $710 million, reflecting continued demand growth globally. In the U.S., year-over-year growth was driven by ongoing adoption in earlier treatment settings and continued expansion of our authorized treatment network. Outside the U.S., growth was supported by launch execution across 20 markets worldwide and continued treatment site activation. Turning to the next slide, we want to provide an update on how we are accelerating growth through our earlier line momentum. Although we do not intend to break this out every quarter, we wanted to provide another update on the traction made in earlier line settings in the U.S. in recent months. This provides clear evidence that we are executing across our objectives.

Alan BashPresident of CARVYKTI

As shown in teal on the far right, patients in the second and third lines represented 50% of CARVYKTI apheresis volume in the U.S. in the third quarter of 2026, which is a significant increase from the 41% in the first quarter of 2026 and 29% in the first quarter of 2025. This trend reflects growing physician confidence in CARVYKTI's benefit-risk profile earlier in the disease course and our ability to reliably support that shift at scale. More broadly, we continue to see meaningful opportunities to expand market penetration as physician familiarity grows and as increasing numbers of eligible patients are referred earlier in their treatment journey, supported by the recent updates to the National Comprehensive Cancer Network guidelines.

Alan BashPresident of CARVYKTI

Turning to the recent NCCN guideline updates from September, the guidelines state that all patients with myeloma should be referred to a T-cell therapy-capable center at the time of first relapse for consideration of available therapies, that when both BCMA CAR-T and T-cell engagers are viable options, current data suggest that CAR-T is preferred given the established efficacy of TCEs following CAR-T cell therapy failure, and third, that prior BCMA-directed therapies should be minimized in patients planning to receive BCMA CAR-T cell therapy. We have been highlighting the updates in our recent discussions with physicians and other stakeholders involved in the development of clinical pathways and will continue to emphasize this new set of recommendations in the coming months.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day